

ALAN J THOMPSON - PUBLICATIONS

BEBO BF, FOX RJ, LEE K, UTZ U, THOMPSON A. Landscape of MS patient cohorts and registries: Recommendations for maximizing impact. *Multiple Sclerosis Journal*, epub ahead of print 1 March 2017.

CAWLEY N, TUR C, PRADOS F, PLANTONE D, KEARNEY H, ABDEL-AZIZ K, OURSELIN S, GANDINI WHEELER-KINGSHOTT CAM, MILLER DH, THOMPSON AJ, CICCARELLI O. Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis. *Multiple Sclerosis Journal*, published online 18th May 2017.

COETZEE T, THOMPSON AJ. When are we going to take modifiable risk factors more seriously in multiple sclerosis? *Multiple Sclerosis Journal* 2017; 23(4):494-495.

HULST H, THOMPSON AJ, GEURTS JJ. The measure tells the tale: Clinical outcome measures in multiple sclerosis. *Multiple Sclerosis Journal*, published online 16 February 2017.

KOBELT G, THOMPSON AJ. Editorial (Costs of multiple sclerosis). *Multiple Sclerosis Journal* 2017; 23 (2_Suppl).

KOBELT G, THOMPSON A, BERG J, GANNEDAHL M, ERIKSSON J, AND THE MSCOI STUDY GROUP, AND THE EUROPEAN MS PLATFORM. New insights into the burden and costs of multiple sclerosis in Europe. *Multiple Sclerosis Journal*, epub ahead of print, 20 February 2017.

MOTL R, FEINSTEIN A, SANDROFF BM, KWAKKEL G, DALGAS U, FEINSTEIN A, HEESSEN C, FEYS P, THOMPSON AJ. The benefits of exercise in patients with multiple sclerosis. *Lancet Neurology*, accepted for publication.

ONTANEDA D, THOMPSON AJ, FOX RJ, COHEN JA. Progressive multiple sclerosis: prospects for disease therapy, repair and restoration of function. *The Lancet* 2017; 389:1357-1366.

SCOLDING NJ, PASQUINI M, REINGOLD SC, COHEN JA, ON BEHALF OF THE INTERNATIONAL CONFERENCE ON CELL-BASED THERAPIES FOR MULTIPLE SCLEROSIS. Cell-based therapeutic strategies for multiple sclerosis. A review article. *Brain* 2017; published online 21 July 2017.

THOMPSON AJ. Multiple Sclerosis: the upward trajectory continues. *Lancet Neurology* 2017;16:10-12.

THOMPSON AJ. Challenge of progressive multiple sclerosis therapy. *Current Opinion in Neurology* 2017; 30(3):237-240.

THOMPSON AJ, KOBELT G, BERG J, CAPSA D, ERIKSSON J, MILLER D. New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom. *Multiple Sclerosis Journal* 2017; 23 (2_suppl):204-216.

BODINI B, CHARD D, ALTMANN DR, TOZER D, MILLER D, THOMPSON A, WHEELER-KINGSHOTT C, CICCARELLI O. White and grey matter damage in primary-progressive MS: the chicken or the egg? *Neurology* 2016; 86(2):170-176.

CICCARELLI O, THOMPSON AJ. Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis. *Nature Reviews Neurology* 2016;12(2):70-72.

ESHAGHI A, WOTTSCHER V, CORTESE R, CALABRESE M, SAHRAIAN MA, THOMPSON AJ, ALEXANDER DC, CICCARELLI O. Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random-forest. *Neurology* 2016; 87(23): 2463-2470.

FREUND P, FRISTON K, THOMPSON A, STEPHAN KE, ASHBURNER J, BACH D, NAGY Z, HELMS G, DRAGANSKI B, SCHWAB M, CURT A, WEISKOPF N. Embodied neurology: An integrative framework for neurological disorders. *Brain* 2016; 139(6):1855-1861.

GRABHER P, MOHAMMADI S, TRACHSLER A, FRIEDL S, GERGELY D, SUTTER R, WEISKOPF N, THOMPSON AJ, CURT A, FREUND P. Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy. *Scientific Reports* 2016; 6; 24636, 20 April.

MARRIE RA, MILLER AE, SORMANI MP, THOMPSON AJ, WAUBANT E, TROJANO M, O'CONNOR P, REINGOLD S, COHEN JA. The challenge of comorbidity in clinical trials for multiple sclerosis. *Neurology* 2016; 86:1446-1453.

MARRIE RA, MILLER AE, SORMANI MP, THOMPSON AJ, WAUBANT E, TROJANO M, O'CONNOR P, FIEST K, REIDER N, REINGOLD S, COHEN JA. Recommendations for observational studies of comorbidity in multiple sclerosis. *Neurology* 2016; 86:1437-1445.

MEIJER KA, MULHERT N, CERCIGNANI M, SETHI V, RON MA, THOMPSON AJ, MILLER DH, CHARD D, GEURTS JGG, CICCARELLI O. White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. *Multiple Sclerosis Journal* 2016; 22(11):1429-1437.

OTERO-ROMERO S, SASTRE-GARRIGA J, COMI G, HARTUNG H, SORENSEN SP, THOMPSON AJ, VERMERSCH P, GOLD R, MONTALBAN X. Pharmacological management of spasticity in multiple sclerosis: systematic review and position paper. *Multiple Sclerosis Journal* 2016; 22(11):1386-1396.

TUR C, GOODKIN O, ALTMANN D, JENKINS TM, MISZKIEL K, MIRIGLIANI A, FINI C, WHEELER-KINGSHOTT C, THOMPSON A, CICCARELLI O, TOOSY A. Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. *Brain* 2016; 139(3):816-828.

VAN DE PAVERT SHP, MUHLERT N, SETHI V, WHEELER-KINGSHOTT CAM, RIDGWAY GR, GEURTS JJG, RON M, YOUSRY TA, THOMPSON AJ, MILLER DH, CHARD DT, CICCARELLI O. DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? *Journal of Neurology Neurosurgery Psychiatry* 2016; 87(5):461-467.

ZARATIN P, COMI G, COETZEE T, RAMSEY K, SMITH K, THOMPSON A, PANZARA M. Progressive MS Alliance Industry Forum: maximizing collective impact to enable drug development. *Trends in Pharmacological Sciences*, published online 15th September 2016.

ABDEL-AZIZ K, SCHNEIDER T, SOLANKY SB, YIANNAKAS MC, ALTMANN DR, WHEELER-KINGSHOTT CAM, PETERS AL, DAY BL, THOMPSON AJ, CICCARELLI O. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. *Brain* 2015; 138:1568-1582.

CAWLEY N, SOLANKY BS, MUHLERT N, TUR C, EDEN R, WHEELER-KINGSHOTT CAM, MILLER DH, THOMPSON AJ, CICCARELLI O. Reduced GABA concentration is associated with physical disability in progressive multiple sclerosis. *Brain* 2015; 138(9):2584-2595.

GRABHER P, CALLAGHAN MF, ASHBURNER J, WEISKOPF N, THOMPSON AJ, CURT A, FREUND P. Tracking sensory system atrophy and outcome prediction in spinal cord injury. *Annals of Neurology* 2015; 78(5):751-761.

RAKUSA M, CANO S, PORTER B, RIAZI A, THOMPSON A, CHATAWAY J, HARDY T. A predictive model for corticosteroid response in individual patients with MS relapses. *PLOS One* 2015; 10(3):0120829.

SALVETTI M, LANDSMAN D, SCHWARZ-LAM P, COMI G, THOMPSON AJ, FOX R. Progressive MS – from pathophysiology to drug discovery. A meeting review (Boston, 2-4 March 2015, 'Progressive MS: finding solutions based on what we know, in spite of what we don't know'). *Multiple Sclerosis Journal* 2015; 21(11): 1376-1384.

THOMPSON AJ. A much-needed focus on progression in multiple sclerosis (Commentary, Reflection and Reaction). *Lancet Neurology* 2015; 14(2):133-135.

TUR C, THOMPSON AJ. Early accurate diagnosis crucial in multiple sclerosis. *The Practitioner* 2015; 259 (1785):21-27.

WOTTSCHHEL V, ALEXANDER DC, KWOK PP, CHARD DT, STROMILLO ML, DE STEFANO N, THOMPSON AJ, MILLER DH, CICCARELLI O. Predicting outcome in clinically isolated syndrome using machine learning. *NeuroImage: Clinical* 2015; 7:281-287.